Gold prices slip lower; consolidating after recent gains
OrbiMed Advisors LLC, a prominent healthcare investment firm, has sold shares in Disc Medicine, Inc. (NASDAQ:IRON) totaling $310,483. The transactions, dated March 24, 2025, involved the sale of 5,738 shares of common stock at a price of $54.11 per share. According to InvestingPro data, the stock currently trades at $52.49, showing significant volatility with a beta of 2.85 and trading between $25.60 and $68.73 over the past 52 weeks.
The sales were reported by multiple entities associated with OrbiMed, including OrbiMed Capital GP VI LLC, OrbiMed Capital GP VIII LLC, and OrbiMed Genesis GP LLC. These transactions resulted in updated holdings of 482,308, 746,171, and 186,541 shares for the respective entities.
The reported transactions are part of OrbiMed’s ongoing portfolio management, highlighting their active engagement in the biotechnology sector. The firm, which holds significant influence in the healthcare investment landscape, continues to exercise strategic decisions in line with market dynamics.
In other recent news, Disc Medicine has been the focus of several analyst updates and strategic developments. Cantor Fitzgerald reaffirmed their Overweight rating for Disc Medicine, maintaining a price target of $99. This decision comes after adjustments to their financial model reflecting the company’s updated share count and operating expenses following a recent public offering. Meanwhile, Scotiabank (TSX:BNS) increased their price target for Disc Medicine to $75, citing plans for a New Drug Application (NDA) submission for bitopertin and anticipated trial results. The firm highlighted the potential launch of bitopertin in 2026, contingent on FDA approval.
TD Cowen initiated coverage on Disc Medicine with a Buy rating, expressing optimism about the market potential for bitopertin and other treatments, including 0974 in the myelofibrosis anemia space. The analyst noted the significant opportunities in these markets, suggesting a positive growth trajectory for the company. Stifel also raised their price target to $94 while maintaining a Buy rating, following Disc Medicine’s authorization to submit an NDA for bitopertin. The firm expressed confidence in the drug’s approval prospects and its commercial potential in treating erythropoietic protoporphyria (EPP).
These developments underscore the dynamic landscape for Disc Medicine, as it progresses with its drug pipeline and strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.